Table 2.
Summary of the results of studies using reduced doses of PTCY with/without ATG in the setting of HLA-mismatched, MRD, and MUD alloHSCT.
| Author | n | Type of Donor | PTCY Dose | Other Immunosuppressant Drugs | II–IV Acute GVHD * | III–IV Acute GVHD * | All-Grade Chronic GVHD ** | Moderate–Severe Chronic GVHD ** |
|---|---|---|---|---|---|---|---|---|
| Juárez et al. | 22 | MRD, MUD | 40 mg/kg/day +3/+4 | Tac | 18.2% | 4.5% | 11.4% | 6.4% |
| Sun et al. [25] | 51 | MRD, MUD | 50 mg/kg/day +3 | ATG + CsA + MMF | 6.2% | 0% | 11.5% | NR |
| Zu et al. [26] | 53 | MRD MUD |
20 mg/kg/day +3/+4 | ATG | 24.5% | NR | 14.1% | NR |
| Solterman et al. [27] | 22 | 1-antigen MMUD | 40 mg/kg/day +3/+4 | CsA + MMF/MTX | 15% | NR | 26% | NR |
| Zhang et al. [28] | 29 | HLA-identical donors | 3 + 3 design trial DL1: 50 mg/kg/day +3/+4 DL2: 50 mg/kg/day +3 and 25 mg/kg/day +4 DL3: 25 mg/kg/day +3/+4 |
CsA | 28.6% (for 21 patients with DL3) | 0% (1 patient at day +141) | 37.3% | 16% |
| García-Cadenas et al. [29] | 14 | MRD MUD 1-antigen MMUD |
30 mg/kg/day +3/+4 | Tac | 28.6% | 7% | 36% | 14% |
* Cumulative incidence at day +100. ** Cumulative incidence at 1-year; NR, Not Reported; DL, dose level.